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Abstract: Cancer is one of the most destructive and lethal illnesses of the modern civilization.
In the last decades, clinical cancer research shifted towards molecular targeted therapies
which have limited side effects in comparison to conventional chemotherapy and radiation
therapy. Anti-angiogenic therapy is one of the most promising cancer treatment methods. The
dynamical model for tumor growth under angiogenic stimulator/inhibitor control was posed
by Hahnfeldt et al. (1999), and it was investigated and partly modified many times. In this
paper, a modified version of the originally published model is used in order to describe a
continuous infusion therapy. To generalize individualized therapies a robust control method
is proposed using H∞ methodology. Uncertainty weighting functions are determined based on
the real pathophysiological case and simulations are performed on different tumor volumes to
demonstrate the robustness of the proposed method.
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1. INTRODUCTION
Cancer is in the front line of lethal illnesses which demands
the highest number of human lives in modern societies
- 7.6 million people worldwide died from cancer in 2008
(World Health Organization (2012)). Because of that,
research and treatment of cancer is a very important
mission for medicine. Beside classical methods there are
a lot of new therapies, based on mathematical models,
where human body works as a complex system.
Antiangiogenic therapy represents a relatively new tar-
geted molecular therapy, which had come up in the last
decade and its aim is to inhibit angiogenesis (creating a
vascular system of the tumor), which leads to the death of
the tumor over the critical volume. (Pluda (1997)).
The main advantage of antiangiogenic therapy to conven-
tional (like chemotherapy) treatments is that tumor cells
can not become resistant towards the antiangiogenic drugs
and antiangiogenic therapy can be used with nontoxic
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concentrations (Kerbel (1997); Qian et al. (2011)). As the
idea is not to eliminate the whole tumor, but to control
and keep it in a given state, model-based treatment, and
hence the use of control theory is an ideal choice. Moreover,
robustness is also important to be able to generalize the
treatment.
Linear H∞ control syntheses are promising methods on
the palette of the robust control systems. This postmodern
technique dates back to around two decades (Doyle et al.
(1989)). Progressively it gains ground by the more and
more powerful computational soft- and hardware (Zhou
(1996); Gu et al. (2005)). One of the biggest advantages of
these methodologies (beyond the well defined mathemat-
ical backgrounds) might be the robustness itself. Robust-
ness against model mismatches, against disturbances.
This current paper is intended to discuss a model-based
angiogenic inhibition of tumor growth by use of H∞
methodology.
The paper is organized as follows. Section 2 gives a short
review of conventional and targeted molecular therapies,
while Section 3 presents the tumor model of our investi-
gations. In Section 4 the H∞ design is summarized, while
simulation results are presented in Section 5. Finally, the
paper ends with the conclusions and future work aspects
in Section 6.
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2. BIOMEDICAL BACKGROUND
Conventional cancer therapies (surgery, chemotherapy, ra-
diotherapy) fight directly against the tumor cells. Surgery
is the oldest modality of cancer therapy, which treats
cancer by removing the gross lesion. Surgical intervention
is most effective in the treatment of localized primary
tumor disease.
Chemotherapy (chemical treatment) is a classical treat-
ment of cancer with anticancer drugs. Choosing the best
suited anticancer drug for a patient is based on the type
of cancer, the patient’s age and health, and other drugs
the patient is taking. Most chemotherapy drugs interfere
with the ability of cells to grow or multiply; hence these
treatments are most effective against rapidly growing cells
(The Free Dictionary (2012)), but it has effects on certain
healthy cells of the patient as well. In addition, tumor cells
can become resistant towards the drug used in chemother-
apy, which makes the usage of new drugs necessary.
Radiotherapy is the medical use of ionizing radiation,
primarily high-energy photons (gamma rays and x-rays)
and charged particles (electrons). Radiation is randomly
deposited within the cell and results DNA damage. This
damage is primarily manifested by the loss of cellular
reproductive integrity. Tumor cells are dividing rapidly, so
the functional disorder resulted by radiotherapy is leading
to cellular death. Similar to chemotherapy, radiation ther-
apy also has effects on healthy cells; therefore, in chemo-
and radiotherapy side effects are significant.
Summarizing conventional cancer therapies (Holland and
Frei (2003)): surgery kills all the excised cells (zero-order
kinetics), in contrast to using chemotherapy or radiation
therapy where only a fraction of tumor cells are killed
(first-order kinetics). When a cancer has been removed
by surgery, chemotherapy or radiotherapy may be used to
keep the cancer from coming back (adjuvant therapy).
Beside conventional therapies, a new approach is repre-
sented by model-based therapies, called targeted molecular
therapies (TMTs). TMTs work by different ways (Li et al.
(2012)) and in contrast to chemo- and radiotherapy, fight
specifically against certain cancer mechanisms (for exam-
ple antiangiogenic inhibitors interfere with cell growth
signaling or stimulate the immune system to destroy spe-
cific cancer cells). By focusing on molecular and cellular
changes that are specific to cancer, targeted molecular
therapies may be more effective than conventional treat-
ments, and less harmful to normal cells (have limited side
effects). The aim of targeted molecular therapies is not to
eliminate the whole tumor, but to control the tumor into
a given state and keep it there.
A promising field in TMTs is antiangiogenic therapy,
which had come up in the last decade (Pluda (1997)).
As rapidly dividing tumor cells need lots of oxygen, when
proliferation begins, small sized tumor can pick up oxygen
from near capillaries. After a certain size (1-2 mm diame-
ter) tumor development stops, because a part of the tumor
gets too far from capillaries and cannot pick up enough
oxygen. Hence, the tumor needs its own blood vessels - the
process of forming new blood vessels is called angiogenesis
(Gotink and Verheul (2010); Kopper and T´ıma´r (2007)).
Angiogenesis occurs normally in the human body at spe-
cific times in embryonic development and growth (for
ex. a developing child in a mother’s womb must create
the vast network of arteries, veins, and capillaries that
are found in the human body). Angiogenesis also takes
place in adults (Kleinsmith et al. (2010)), although it
is a relatively infrequent event (in case of high altitude
(low oxygen concentration), regeneration of tissue during
wound healing and in women during certain phases of the
menstrual cycle). In such cases, angiogenesis starts due
to typical molecular triggers and ends when the necessary
processes are completed.
However, tumors can break through this precise control.
The aim of antiangiogenic cancer therapy is to prevent
tumors from forming new blood vessels, because without
angiogenesis tumor growth is inhibited. Several angiogenic
inhibitors are known in medical practice, for ex. endostatin
(O’Reilly et al. (1997)) or bevacizumab (Ellis and Haller
(2008)). Contrary to conventional treatments, using an-
tiangiogenic therapy, tumor cells cannot become resistant
towards the antiangiogenic drugs (this is achieved by an-
tiangiogenic therapy as it is directed against the tumor
supplying blood vessels) Kerbel (1997) and antiangiogenic
therapy can be used with nontoxic concentrations (Qian
et al. (2011)). However, due to high costs of the antiangio-
genic drugs, their optimal usage is preferred which gives
an ideal field for model-based and optimal control theory.
3. DYNAMICAL MODEL OF TUMOR GROWTH
At the Harvard Medical University, Hahnfeldt et al. (1999)
comprised the complete model formulation for tumor
growth control under the actions of angiogenic stimulation
and inhibition. In their experience, mice were injected with
Lewis lung carcinoma cells.
From the original model one can derive the following
second-order system (Hahnfeldt et al. (1999)):
x˙1 = −λ1x1 ln
(
x1
x2
)
(1)
x˙2 = bx1 − dx2/31 x2 − ex2u (2)
y = x1 (3)
where x1 is the tumor volume (mm3), x2 is the sup-
porting vasculature volume (mm3), and u is the serum
level of the inhibitor (mg/kg). The parameters char-
acteristic for the Lewis lung carcinoma and the mice
used in the experiment are: λ1=0.192 (day−1) describing
the speed of the Gompertzian growth, b=5.85 (day−1)
describing the stimulating effect of the tumor on an-
giogenesis, d=0.00873 (day−1mm−2) describing inher-
ent angiogenic inhibition effects, and the parameter
characteristic for the applied inhibitor (endostatin) is:
e=0.66 (day−1(mg/kg)−1) describing the effect of an-
giogenic inhibition on the supporting vasculature. These
numerical values of the model parameters will be used
throughout the paper, both at the controller design and
simulation phases.
Fig. 1. shows the tumor growth slowdown and asymp-
totic limit (17340 mm3) of Lewis lung tumor size that
would hypothetically be reached if this size of tumor were
compatible with the life of the animal (see upper part
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Fig. 1. Tumor growth without and under angiogenic inhi-
bition
of Fig. 1, being equivalent of an open-loop therapy. This
is also equivalent to a lethal steady-state case). Under
anti-angiogenic treatment (constant 5 mg/kg endostatin),
initiated from the largest tumor volume, tumor size is
projected to plateau as a result of parallel plateauing of
available vascular support. Angiogenic inhibitors act to
generate lower plateau points (see lower part of Fig. 1,
equivalent to a model-based therapy, but yet without con-
trol strategy).
Since the aim of this work is to design robust control for
the system, deriving a linear model is necessary, as the
H∞-control design requires a linear nominal model. The
linear model is acquired by working point linearization.
The symbolic form of the linearization is:
x˙1 =
(
−λ1 ln
(
x10
x20
)
− λ1
)
x1 + λ1
x10
x20
x2 (4)
x˙2 =
(
b− 2
3
dx
− 13
10 x20
)
x1 +
(
−dx 2310 − eu0
)
x2 − ex20u
(5)
y = x1. (6)
The non-trivial equilibrium points of the linearized model
can be calculated from (4), i.e. x10 = x20. The assessed
working point is x10 = x20 = 100 mm3, u0 = 5 mg/kg,
(Drexler et al. (2011)). The eigenvalues of the linearized
system are p1 = 0.1132 and p2 = −3.7933, p1 is on the
right-half plane, thus the system is unstable, correspond-
ing to the pathophysiological case. After evaluating the
controllability and the observability criteria, one gets that
the system is controllable and observable.
4. H∞ CONTROL DESIGN
The objective of the problem is to design a linear, robust
controller, which achieves good tracking property, takes
into account the model uncertainties and limits the magni-
tude of the control input and the disturbance. The signals
of the system are the following: r is the reference, u is the
control input, y is the output, n is the measurement noise,
e is the modeling error, d is the disturbance caused by the
uncertainty of the model, zu is the penalized control input,
whereas ze is the deviation of the output from the required
one (Fig. 2).
The closed-loop system includes the feedback structure of
the nominal model Gn and the two-degree controller K,
which is portioned in two parts: Ky is the feedback part
to meet the requirements of internal and robust stability,
disturbance rejection, measurement noise attenuation, and
sensitivity minimisation, while Kr is the prefilter part,
which optimises the response of the overall system to the
command input such that the output of the system would
be near to that of the chosen ideal system.
The input multiplication uncertainty Wunc takes into
consideration the differences between the nominal model
and the real plant. The weighting function Wn stands
for the limitation of sensor noise. The limitation of the
control input is achieved by the weighting function Wu
which penalizes larger deflections. The model matching
function Tid describes the ideal transfer function of the
plant. Since the designed controller should effect tumor
regression even in the worst case, the reference model, Tid
describes fast regression from the maximal tumor volume
predicted by the model. The weighting function Wperf
penalizes tracking.
Starting from the formal definition of the multiplicative
uncertainty, parametric sensitivity was performed on the
nonlinear model to determine Wunc. The idea was par-
tially adapted and modified from Liu and Tang (2008)
and Kova´cs et al. (2011). The idea is to take uncertain
parameters in the nonlinear model. After taking every
single extremal combination of the parameters using a
gridding technique, linearization is performed. In our case
a {±5%, ±2.5%, 0%} grid was used for the variability
of the Lewis lung carcinoma parameters (b, d), and a
{±10%, ±5%, 0%} grid was used for vascular inactivation
rate (e).
Finally, the frequency content of the perturbed and lin-
earized model is compared, and relative difference is com-
puted,
Wrel(ω) =
∣∣∣∣Gp(ω)−Gn(ω)Gn(ω)
∣∣∣∣ (7)
where Gp stands for the perturbed model and Gn for the
nominal one.
The obtained uncertainty weighting function, Wunc should
work as a high pass filter to reduce disturbance at low fre-
quency, and to avoid strong restrictions at high frequency.
Sensor-noise, as a wide-band signal, can be modeled with
a constant value. During the design process, Wn antici-
pates 5% measurement noise for volume measurements.
The weight on endostatin inlet, Wu is defined to be con-
stant over the entire frequency range and with a magni-
tude equal to the inverse of the maximal possible inlet
(1/100 mg/kg), because of physiological reasons (since
high doses are not desirable). Wperf should be large in
frequency range where small errors are desired and small
where larger errors can be tolerated. The chosen weighting
functions can be seen in Fig. 3.
The generalized structure of H∞ control design is formu-
lated in ∆–P–K structure, (Fig. 4). As signals, w∗ = [r n]
denotes the external inputs, z∗ = [ze zu] represents the
output signals to be minimized or penalized. The closed-
loop function M can be derived as the lower linear frac-
tional transformation of the pair (P,K).
8th IFAC Symposium on Biological and Medical Systems
August 29-31, 2012. Budapest, Hungary
115
de
u y
r
-
-
n
z
ze
u
W
W
W
perf
u
n
Gn
Ky
Kr
Wunc
T id
unc
Fig. 2. The closed-loop interconnection structure
10−3 10−2 10−1 100 101 102
10−6
10−5
10−4
10−3
10−2
10−1
Weighting functions
Frequency (rad/day)
M
ag
ni
tu
de
 
 
Wunc − Uncertainty weighting function
Wperf − Performance weighting function
Wu − Control input weighting function
Wn − Sensor noise weighting function
Fig. 3. Weighting functions in frequency domain
u
z
r y
P
K[ ]
w
d e
* *
M
Fig. 4. The generalized ∆–P–K structure
The aim of the suboptimal design is to find a stabilising
controller K such that the H∞-norm of the closed-loop
function is less than a given positive number, Zhou (1996),
i.e.,
‖M‖∞ = ‖F`(P,K)‖∞ < γ. (8)
The scope of the H∞ controller design is to guarantee
robust performance of the system. This can be realized
by fulfilling the conditions of robust stability and nominal
performance. To guarantee nominal stability the system
must be internally stable, which means that the created
transfer function is stable from all inputs to all outputs.
The robust stability is achieved by fulfilling the following
condition:
‖M11‖∞ < 1. (9)
The nominal performance is achieved if the performance
objective is satisfied:
‖M22‖∞ < 1. (10)
As a result, the conditon of robust performance is equiva-
lent with the following, Zhou (1996):
‖Fu(M,∆)‖∞ < 1. (11)
5. SIMULATION RESULTS
The frequency domain analysis (Fig. 5.) showed that the
conditions of robust stability (9), nominal performance
(10) and robust performance (11) are fulfilled, since all
the corresponding norms are smaller than 1. The achieved
γ value was 0.0488, and the designed controller proved to
be stable since its poles are on the left-half plane. Con-
sequently, the designed controller is suitable for practical
applications. The dominant singular values of the closed-
loop system have shown that the entire system could be
modeled with a second order system (Szeles (2012)).
The time domain analysis showed that control input sat-
uration is necessary, since the magnitude of the controller
output was not acceptable physiologically. The simulation
was carried out in case of different saturation levels from
different initial tumor volumes. In Fig. 6 one can see
that tumor volume reaches a steady-state point during
the treatment, which attained by the ongoing treatment
is independent of the tumor volume at which therapy
initiated, and depends only on how the ongoing treatment
modulates the balance between angiogenic stimulaters and
inhibitors.
At the beginning of the treatment the inhibitor serum level
holds a higher constant value, after a while decreases to
a lower constant value. The higher the maximal possible
serum level of endostatin, the sooner the reduction of the
dose is possible (Fig. 7).
Beside maximizing the efficiency of the treatment, another
challenge is to minimize the caused strain on the body and
the costs of the treatment. The aim of this assess is to show
the variation of the total inhibitor inlet as a function of the
initial tumor volume and the maximal endostatin inlet. In
Fig. 8 one can see how total inhibitor inlet varies with the
initial tumor volume.
Higher saturation level can be beneficial in case of fast
tumor regression. However, higher inhibitor serum level
infers higher total inlet of endostatin, which has to be
taken in consideration while planning the therapy.
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This paragraph investigates the properties of the closed-
loop system if the tumor growth model is linearized
at diverse working points and the controller design is
performed on the latter models, as nominal models. The
set point attained by the ongoing treatment and the
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Fig. 8. Inhibitor inlet during the entire treatment
constant inhibitor serum level necessary to retain the
tumor volume at a lower level are functions of the working
point of the linearization (Fig. 9). The higher the working
point of the linearization, the higher the plateau attained
and the lower the angiogenic inhibitor serum level required
to obtain balance between angiogenic stimulaters and
inhibitors.
A controller, which is able to switch between different
working points, could achieve good performance at smaller
working points, though it could not significantly exceed
the performance of the controller presented in the entire
domain of interest. Additionally, at larger working points
strong deterioration can be expected. Controllers designed
at larger operation points show deficiency in diminution of
tumor volume, because the magnitude of the control signal
is notably limited, (Fig. 10).
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Fig. 9. Minimal tumor volume attained by the treatment
and control input required at the plateau
Consequently, good performance, fast tumor regression
and small final tumor size can be achieved, if the controller
design is performed on a nominal model linearized at small
working point, and the controller output is weakly satu-
rated (50-100 mg/kg). From physiological aspect, moder-
ately saturated (20-30 mg/kg) inhibitor level is reasonable.
Hence, the duration of the treatment is not extreme long,
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and neither the inhibitor serum level nor the total inlet
exceeds an acceptable limit.
6. CONCLUSION
In the course of H∞ design robust stability, nominal
performance and robust performance were achieved. The
properties of the closed-loop system were investigated
varying the tumor volume at which treatment was initi-
ated, and at which the nominal model, used by the con-
troller design, was linearized. Tumor regression and total
inhibitor inlet was assessed at different saturation levels of
the controller output. The controllers, designed at small
working points, showed robustness of high degree against
the nonlinearities of the system. Good performance, fast
tumor regression and small final tumor size were achieved.
Further work will be related to µ-synthesis design, but
also on the use of nonlinear control methods and optimal
control (Pontryagin (1962), Precup and Preitl (2004)).
Higher order model synthesis will be also performed.
A further aim of research is modeling and controlling
combined therapy and validate it on animal experiments.
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